Flag Ship Acquisition Stock Scheduled to Reverse Split on Monday, October 20th (NASDAQ:ETHZ)

Key Points

• Flag Ship Acquisition Corp. (NASDAQ:ETHZ) is set to undergo a 1-for-10 reverse stock split on Monday, October 20th, with share adjustments happening after the market closes on October 17th.
• The company currently has a market capitalization of $300.91 million and a consensus analyst rating of "Sell", indicating negative sentiment among analysts regarding its stock.
• Flag Ship Acquisition has seen significant price fluctuations, with a 12-month low of $0.66 and a high of $17.75 for its shares.

Flag Ship Acquisition Corp. (NASDAQ:ETHZ - Free Report)'s stock is going to reverse split on the morning of Monday, October 20th. The 1-10 reverse split was announced on Wednesday, October 15th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, October 17th.

Flag Ship Acquisition Stock Performance

Shares of ETHZ opened at $1.83 on Thursday. The stock has a market capitalization of $300.91 million, a P/E ratio of -0.12 and a beta of 0.38. Flag Ship Acquisition has a 12-month low of $0.66 and a 12-month high of $17.75.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ETHZ shares. Wall Street Zen lowered shares of Flag Ship Acquisition to a "strong sell" rating in a report on Saturday, August 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Flag Ship Acquisition in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of "Sell".

About Flag Ship Acquisition

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.